Navigation Links
GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act'
Date:3/17/2009

ARLINGTON, Va., March 17 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the introduction of H.R. 1548, "The Pathway for Biosimilars Act."

"The Pathway for Biosimilars Act is the wrong road for patients looking for safe and affordable biogeneric medicines, particularly during these difficult economic times. It is a long route filled with needless roadblocks that will keep patients from getting needed medicines in a timely manner.

"To increase competition and ensure timely patient access, Congress needs to enact a workable pathway without unnecessary barriers. The bipartisan consensus bill, the Promoting Innovation and Access to Lifesaving Medicine Act, introduced last week achieves the balance of fostering pharmaceutical innovation while also making affordable medicines available to consumers. This bipartisan bill recognizes our health care system's successful experience with generic medicines for the past 25 years. The market exclusivity provisions in Hatch-Waxman have clearly demonstrated that we can achieve the much-needed balance between pharmaceutical competition and innovation for the benefit of consumers, payors and state and federal governments.

"That's why consumer, business and labor organizations, AARP and many of our nation's governors support the Promoting Innovation and Access to Lifesaving Medicine Act that brings biogeneric medicines to consumers sooner rather than later through timely resolution of patent disputes and market exclusivity provisions consistent with the Hatch-Waxman model.

"Unfortunately, The Pathway for Biosimilars Act is the wrong medicine for patients and our nation's health care system. This bill will only benefit brand companies by erecting barriers including an unprecedented and unjustifiable 14 years of market exclusivity. Given that there is a minimal difference of less than eight months longer in the development of biopharmaceuticals when compared to traditional pharmaceuticals, there is little justification for excessively expanding exclusivity beyond the Hatch-Waxman model. Excessive exclusivity means that it will be decades before patients have access to affordable biogeneric medicines. For the countless patients who are choosing between paying for their medicines and putting food on their tables, waiting decades is simply not an option.

"Timely access to affordable biogenerics will save lives and save consumers and state and federal governments billions of dollars. The time has come for a truly workable pathway, not a pathway in name only."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE The Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... Each year, about ... cause of death across the United States and account for one death every four ... impairments or are permanently disabled. HCR ManorCare is launching a video series called “Your ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announced today that Legacy Health is expanding its use of Intrigma’s cloud-based physician ... highly successful initial proof of concept. The Portland, Oregon based health system conducted ...
(Date:5/3/2016)... VA (PRWEB) , ... May 03, 2016 , ... ... provider of innovative information technology (IT) solutions and digital consulting services to the ... Information Technology Services (EITS) Indefinite Delivery / Indefinite Quantity (ID/IQ) contract in support ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic doctor , ... procedure that can be used to diagnose and treat joint problems. During this procedure, ... instruments include a special lighting system and lens that illuminate and magnify the various ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
Breaking Medicine Technology: